Results for tag: "Prostatic Hypertrophy Drug"

Prostatic Hypertrophy Drug market is a subset of the Prostate Cancer Drugs market. It is composed of drugs used to treat benign prostatic hyperplasia (BPH), a condition in which the prostate gland enlarges and causes urinary symptoms. These drugs are typically used to reduce the size of the prostate and improve urinary flow. Commonly used drugs include alpha-blockers, 5-alpha reductase inhibitors, and antimuscarinics. Alpha-blockers work by relaxing the muscles of the prostate and bladder neck, while 5-alpha reductase inhibitors reduce the production of dihydrotestosterone, a hormone that can cause prostate enlargement. Antimuscarinics work by blocking the action of acetylcholine, a neurotransmitter that can cause bladder muscle contractions. Companies in the Prostatic Hypertrophy Drug market include Pfizer, Merck, Astellas, Sanofi, and Allergan. Show Less Read more